Skip to content Skip to footer
CSPC pharma & Radiance Biopharma

CSPC Pharmaceutical Collaborates with Radiance Biopharma to Develop and Commercialize RB-164 (SYS6005) as an Anti-Cancer Therapy

Shots:CSPC has granted Radiance exclusive rights to develop & market RB-164 in the US, Canada, EU, UK, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, & Australia, while retaining rights to other markets As per the deal, CSPC will get $15M upfront, ~$150M in development & regulatory milestones and ~$1B in commercial…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]